Innovative dosage forms of nifedipine: assortment and development prospects

Author:

Tokaev V.V., ,Lobanova L.V.,

Abstract

Nifedipine is one of the most commonly prescribed drugs in the treatment of diseases of the cardiovascular system. Due to the relatively small number of dosage forms of this drug and its minimal production in the Russian Federation, the creation of new dosage forms of nifedipine represented by a transdermal patch and transdermal gel is a feasible and urgent task. Nifedipine has a fairly wide use in cardiological practice; according to the results of many years of research, it has been proved that this drug is used in such areas of medicine as mountain medicine, psychiatry, gynecology, and gerontology. Despite the complexity of creating transdermal forms, the number of medicinal substances delivered by percutaneous diffusion is gradually increasing. A significant disadvantage of nifedipine is its low solubility in water, which significantly affects the degree of release of the pharmaceutical substance from the drug base. Owing to the absence of nifedipine-based transdermal therapeutic systems on the pharmaceutical market, their development is an urgent problem of modern pharmacy in order to improve the biopharmaceutical properties of a pharmaceutical substance.

Publisher

PANORAMA Publishing House

Reference9 articles.

1. 1. The State Register of Medicines of the Russian Federation: [website]. URL: htpp:// grls.ros-minzdrav.ru / Default. aspx

2. 2. Kukes V.G. Are all prolonged dosage forms of nifedipine the same / V.G. Kukes, D.A. Sychev. Rational Pharmacotherapy in Cardiology. 2018; 1: 49-54.

3. 3. Leonova M.V. Characteristics of modified-release nifedipine dosage forms and their significance in the treatment of cardiovascular diseases. Atmosphere. 2019; 3: 14-20.

4. 4. Martsevich. S.Yu. Nifedipin: as shown by 30 years of clinical use experience. Cardiovascular therapy and prevention. 2018; 4: 4-8.

5. 5. Martsevich, S.Yu. The effectiveness of a new dosage form of nifedipine of prolonged action -nifecarda - XL in the treatment of arterial hypertension / S.Yu. Martsevich, E.V. Alimova, V.M. Gorbunov [et al.]. Russian Journal of Cardiology. 2018; 5: 55-58.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3